Sidebar

  • Magazine
  • Events
  • Videos
  • Gallery
  • Blog
  • Gantry Home

Magazine menu

  • Home
  • News
    • China News
    • Religion
  • lifestyle
  • Tech
  • Financial
  • Military
  • Entertainment
  • Politics
  • Health
  • Sport
  • Environment
  • Opinion
  • Weather
  • Podcasts
  • Video
  • Ads
The Power of Truth®
Saturday, May 10, 2025
Saturday, May 10, 2025
  • Home
  • News
    • China News
    • Religion
  • lifestyle
  • Tech
  • Financial
  • Military
  • Entertainment
  • Politics
  • Health
  • Sport
  • Environment
  • Opinion
  • Weather
  • Podcasts
  • Video
  • Ads
  1. You are here:  
  2. Health

New data on Mpox vaccine effectiveness

Details
Staff logo
19 March 2025
Health
  • Previous Article What nine months in space does to the human body
  • Next Article Shaping the future of diabetes treatment with 3D bioprinting technology
A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended.
A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended.

Read more https://www.sciencedaily.com/releases/2025/03/250319143643.htm

  • Previous Article What nine months in space does to the human body
  • Next Article Shaping the future of diabetes treatment with 3D bioprinting technology

HUNGRY FOR TRUTH?  FEED THE NEED.

The Power of Truth®
  • Cookies Policy
  • Privacy Policy
  • Terms of Use
  • Contact
Copyright © 2025 Joomla!. All Rights Reserved. Powered by The Power of Truth® - Designed by JoomlArt.com. Bootstrap is a front-end framework of Twitter, Inc. Code licensed under Apache License v2.0. Font Awesome font licensed under SIL OFL 1.1.